drugset / Trial / NCT06304961

A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

NCT06304961

Phase 1 Completed 46 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The study will assess the relative bioavailability between two dosage forms of tozorakimab (test dosage form and reference dosage form) and to assess the pharmacokinetic (PK) profiles of both dosage forms.

Timeline

Start
2024-04-08
Primary completion
2024-09-09
Completion
2024-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tozorakimab Monoclonal antibody Subcutaneous

Indications

No indication recorded.